Insulin Pump Therapy in Patients with Type 1 Diabetes Mellitus: Results of the Nationwide Quality Circle in Germany (ASD) 1999 - 2000

Abstract

Background and Aims

Only a few specialised centres in Germany initiated insulin pump therapy before 1990. Initiation of pump therapy involves the participation in a structured treatment and teaching programme (TTP). During the last decade insulin pump therapy has been widely used. The impact of this decentralisation on the quality of care is still unknown. The aim of this trial was both to evaluate the outcome of insulin pump therapy outside specialised centres and to identify features that might be associated with persistently increased HbA1 c levels.

Patients and Methods

250 patients with type 1 diabetes mellitus (age 36.0 ± 13.1 years; diabetes duration 16.1 ± 9.9 years), who were on continuous subcutaneous insulin infusion (CSII) therapy during 1999 - 2000, were individually included in the study. Second examination was performed one year after participation in the in-patient TTP for insulin pump therapy. Patients were recruited from 21 member institutions of the Working Group for Structured Diabetes Therapy of the German Diabetes Association. Further details were sought by questionnaire on those patients with persistently increased HbA1c (> 1.7fold of mean normal range.)

Results

One year after participation in the TTP for CSII relative HbA1c (original value/mean normal of the local method [Müller et al., 1999]) decreased from 1.51 (0.9 - 3.2) to 1.44 (0.9 - 3.6) (p < 0.0001), severe hypoglycaemia from 0.46 to 0.12/patient/year (p < 0.001), severe ketoacidosis from 0.08 to 0.05/patients/year (p = 0.003) and hospitalisation from 5.2 to 3.1 days/patient/year (p = 0.002). In 43/207 (17 %) the incidence of severe hypoglycaemia was unchanged (before 0.12 and after TTP 0.14/patients/year), there was slight increase in severe ketoacidosis (before 0.15; after TTP 0.23/patients/year) and hospitalisation days were unchanged (before 4.5; after TTP 4.4 days/patients/year). The following factors were associated with adverse outcomes: psychological problems including eating disorders and alcohol abuse (28 %), lack of interest in self-management (28 %) and social problems (11 %). In 28 % there was no follow-up treatment by diabetologists specialised in pump therapy.

Conclusion

The benefits of insulin pump therapy are improvement of HbA1c, reduction of hypoglycaemia, ketoacidosis and hospitalisation days as well as improved flexibility. It is possible to draw up a list of clinical criteria and service requirements, which are likely to reduce failures.

Insulin pump therapy - hypoglycaemia - ketoacidosis - hospitalisation days - psychological problems

References

• 1 American Diabetes Association . Policy statement: Continuous subcutaneous insulin infusion.  Diabetes. 1985;  34 946-947
• 2 Bending J J, Pickup J C, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care.  Am J Med. 1985;  79 685-691
• 3 Berger M, Jörgens V. Praxis der Insulintherapie: Therapie mit Insulinpumpen. Berlin, Heidelberg, New York; Springer-Verlag 2001
• 4 Bode B W, Steed R D, Davidson P C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes.  Diabetes Care. 1996;  19 324-327
• 5 Boland E A, Grey M, Oesterle A, Fredrickson L, Tamborlane W V. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.  Diabetes Care. 1999;  22 1779-1784
• 6 Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience.  Diabetologia. 1989;  32 421-426
• 7 Gens E, Kerner W. Prospektive Evaluation der Insulinpumpentherapie bei 98 Kindern und Jugendlichen mit Diabetes mellitus Typ I im Zeitraum von 1993 bis 1999.  Diabetes und Stoffwechsel. 2001;  10 52
• 8 Gronwald S, Heinke P, Kerner W. Verlauf von Stoffwechselparametern und Diabetes-Komplikationen bei 314 Typ-I-Diabetikern unter Insulinpumpentherapie (CSII) über 5 Jahre.  Diabetes und Stoffwechsel. 2001;  10 53
• 9 Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.  Diabetes Care. 2000;  23 1232-1235
• 10 Jörgens V, Grüßer M, Bott U, Mühlhauser I, Berger M. Effective and safe translation of intensified insulin therapy to general internal medicine departments.  Diabetologia. 1993;  36 99-105
• 11 Kademann A, Schiel R, Hunger-Dathe W, Müller U A. Effektivität der Insulinpumpentherapie im Vergleich zur intensivierten konventionellen Insulintherapie.  Diabetes und Stoffwechsel. 1999;  7 118-124
• 12 Kanc K, Janssen M M, Keulen E T, Jacobs M A, Popp-Snijders C, Snoek F J. et al . Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.  Diabetologia. 1998;  41 322-329
• 13 Krans H MJ, Porta M, Keen H, Staehr J K. Diabetes care and research in Europe: the St. Vincent Declaration action programme. Implementation document.  G Ital Diab. 1995;  15 1-84
• 14 Lock D R, Rigg L A. Hypoglycemic coma assosciated with subcutaneous insulin infusion by portable pump.  Diabetes Care. 1981;  4 389-391
• 15 Mecklenburg R S, Benson E A, Benson J W, Fredlund P N, Guinn T, Metz R J. et al . Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients.  JAMA. 1984;  252 3265-3269
• 16 Mühlhauser I. Hypoglykämie. München, Wien, Baltimore; Urban & Schwarzenberg 1995
• 17 Müller U A, Femerling M, Risse A, Reinauer K M, Voss M, Jörgens V. et al . Intensifed treatment and education of type-1 diabetes as clinical routine: A nation-wide quality-circle experience in Germany.  Diabetes Care. 1999;  22 B29-B34
• 18 Müller U A, Femerling M, Risse A. HbA1c and severe hypoglycemia after intensified treatment and education of 10, 000 type-1-diabetic patients. Results of a ten year nationwide quality-circle.  Diabetologia. 2001 a;  44 A16
• 19 Müller U A, Hunger-Dathe W, Braun A, Femerling M, Risse A. Efffektivität der kontinuierlichen subkutanen Infusionstherapie bei Diabetes mellitus Typ-1 nach Schulung in Kliniken der Arbeitsgemeinschaft für strukturierte Diabetestherapie (ASD).  Diabetes und Stoffwechsel. 2001 b;  10 106-107
• 20 Müller U A, Köhler S, Femerling M, Risse A, Schumann M, Götz U. et al . HbA1c und schwere Hypoglykämien nach intensivierter Behandlung von Patienten mit Typ-1-Diabetes als klinische Routine: Ergebnisse eines deutschlandweiten Qualitätszirkels (ASD) 1992 - 1999.  Diab Stoffw. 2000;  9 67-81
• 21 Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes.  Diabetes Care. 2002;  25 593-598
• 22 Renner R. Versuche mit neuen Behandlungsmethoden: Insulinpumpen, künstliches Pankreas. Stuttgart, New York; Georg Thieme Verlag 1984
• 23 Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.  Diabetes Care. 1999;  22 784-788
• 24 Schiel R MU, Sprott H, Schmelzer A, Mertes B, Hunger-Dathe W, Ross I S. The JEVIN trial: A population based survey on the quality of diabetes care in Germany 1994/95 versus 1989/90.  Diabetologia. 1997;  40 1350-1357
• 25 Schiel R, Müller U A, Sprott H, Schmelzer A, Mertes B, Hunger-Dathe W. et al . The JEVIN trial: A population based survey on the quality of diabetes care in Germany 1994/95 versus 1989/90.  Diabetologia. 1997;  40 1350-1357
• 26 The Diabetes Control and Complication Trial Research Group . Implementation of treatment protocols in the diabetes control and complications trial.  Diab Care. 1995;  18 361-376
• 27 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 28 The expert committee on the diagnosis and classification of diabetes mellitus . Report of the committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1193
• 29 Thurm U. Insulinpumpenfibel. 4th edition, Switzerland; Disetronic GmbH 2001
• 30 Wredling R, Hannerz L, Johansson U B. Variability of blood glucose levels in patients treated with continuous subcutaneous insulin infusion: a pilot study.  Practical Diabetes Int. 1997;  14 5-8
• 31 Wredling R, Lins P E, Adamson U. Factors influencing the clinical outcome of continuous subcutaneous insulin infusion in routine practice.  Diabetes Res Clin Pract. 1993;  19 59-67